Adi Gazdar1, Linda Robinson, Dwight Oliver, Chao Xing, William D Travis, Junichi Soh, Shinichi Toyooka, Lori Watumull, Yang Xie, Kemp Kernstine, Joan H Schiller. 1. *Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, TX; †Department of Pathology, UT Southwestern Medical Center, Dallas, TX; ‡Cancer Genetics, Simmons Cancer Center, UT Southwestern Medical Center, Dallas, TX; §Department of Clinical Science and McDermott Center for Human Growth and Development, UT Southwestern Medical Center, Dallas, TX; ‖Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY; ¶Department of Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan; #Department of Radiology, UT Southwestern Medical Center, Dallas, TX; **Department of Clinical Science and Simmons Cancer Center, UT Southwestern Medical Center, Dallas, TX; ††Department of Cardiovascular and Thoracic Surgery, UT Southwestern Medical Center, Dallas, TX; and ‡‡Department of Medicine and Simmons Cancer Center, UT Southwestern Medical Center, Dallas, TX.
Abstract
INTRODUCTION: Hereditary lung cancer syndromes are rare, and T790M germline mutations of the epidermal growth factor receptor (EGFR) gene predispose to the development of lung cancer. The goal of this study was to determine the clinical features and smoking status of lung cancer cases and unaffected family members with this germline mutation and to estimate its incidence and penetrance. METHODS: We studied a family with germline T790M mutations over five generations (14 individuals) and combined our observations with data obtained from a literature search (15 individuals). RESULTS: T790M germline mutations occurred in approximately 1% of non-small-cell lung cancer cases and in less than one in 7500 subjects without lung cancer. Both sporadic and germline T790M mutations were predominantly adenocarcinomas, favored female gender, and were occasionally multifocal. Of lung cancer tumors arising in T790M germline mutation carriers, 73% contained a second activating EGFR gene mutation. Inheritance was dominant. The odds ratio that T790M germline carriers who are smokers will develop lung cancer compared with never smoker carriers was 0.31 (p = 6.0E-05). There was an overrepresentation of never smokers with lung cancer with this mutation compared with the general lung cancer population (p = 7.4E-06). CONCLUSION: Germline T790M mutations result in a unique hereditary lung cancer syndrome that targets never smokers, with a preliminary estimate of 31% risk for lung cancer in never smoker carriers, and this risk may be lower for heavy smokers. The resultant cancers share several features and differences with lung cancers containing sporadic EGFR mutations.
INTRODUCTION: Hereditary lung cancer syndromes are rare, and T790M germline mutations of the epidermal growth factor receptor (EGFR) gene predispose to the development of lung cancer. The goal of this study was to determine the clinical features and smoking status of lung cancer cases and unaffected family members with this germline mutation and to estimate its incidence and penetrance. METHODS: We studied a family with germline T790M mutations over five generations (14 individuals) and combined our observations with data obtained from a literature search (15 individuals). RESULTS:T790M germline mutations occurred in approximately 1% of non-small-cell lung cancer cases and in less than one in 7500 subjects without lung cancer. Both sporadic and germline T790M mutations were predominantly adenocarcinomas, favored female gender, and were occasionally multifocal. Of lung cancer tumors arising in T790M germline mutation carriers, 73% contained a second activating EGFR gene mutation. Inheritance was dominant. The odds ratio that T790M germline carriers who are smokers will develop lung cancer compared with never smoker carriers was 0.31 (p = 6.0E-05). There was an overrepresentation of never smokers with lung cancer with this mutation compared with the general lung cancer population (p = 7.4E-06). CONCLUSION: Germline T790M mutations result in a unique hereditary lung cancer syndrome that targets never smokers, with a preliminary estimate of 31% risk for lung cancer in never smoker carriers, and this risk may be lower for heavy smokers. The resultant cancers share several features and differences with lung cancers containing sporadic EGFR mutations.
Authors: Daphne W Bell; Ira Gore; Ross A Okimoto; Nadia Godin-Heymann; Raffaella Sordella; Roseann Mulloy; Sreenath V Sharma; Brian W Brannigan; Gayatry Mohapatra; Jeff Settleman; Daniel A Haber Journal: Nat Genet Date: 2005-10-30 Impact factor: 38.330
Authors: Douglas B Flieder; Madeline Vazquez; Darryl Carter; Elizabeth Brambilla; Adi Gazdar; Masayuki Noguchi; William D Travis; Arin Kramer; David F Yankelevitz; Claudia I Henschke Journal: Am J Surg Pathol Date: 2006-05 Impact factor: 6.394
Authors: Heather A Wakelee; Ellen T Chang; Scarlett L Gomez; Theresa H Keegan; Diane Feskanich; Christina A Clarke; Lars Holmberg; Lee C Yong; Laurence N Kolonel; Michael K Gould; Dee W West Journal: J Clin Oncol Date: 2007-02-10 Impact factor: 44.544
Authors: Thomas S Frank; Amie M Deffenbaugh; Julia E Reid; Mark Hulick; Brian E Ward; Beth Lingenfelter; Kathi L Gumpper; Thomas Scholl; Sean V Tavtigian; Dmitry R Pruss; Gregory C Critchfield Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: Hisayuki Shigematsu; Li Lin; Takao Takahashi; Masaharu Nomura; Makoto Suzuki; Ignacio I Wistuba; Kwun M Fong; Huei Lee; Shinichi Toyooka; Nobuyoshi Shimizu; Takehiko Fujisawa; Ziding Feng; Jack A Roth; Joachim Herz; John D Minna; Adi F Gazdar Journal: J Natl Cancer Inst Date: 2005-03-02 Impact factor: 13.506
Authors: Helena A Yu; Maria E Arcila; Natasha Rekhtman; Camelia S Sima; Maureen F Zakowski; William Pao; Mark G Kris; Vincent A Miller; Marc Ladanyi; Gregory J Riely Journal: Clin Cancer Res Date: 2013-03-07 Impact factor: 12.531
Authors: William Pao; Vincent A Miller; Katerina A Politi; Gregory J Riely; Romel Somwar; Maureen F Zakowski; Mark G Kris; Harold Varmus Journal: PLoS Med Date: 2005-02-22 Impact factor: 11.069
Authors: Erin M Parry; Dustin L Gable; Susan E Stanley; Sara E Khalil; Valentin Antonescu; Liliana Florea; Mary Armanios Journal: J Thorac Oncol Date: 2017-08-24 Impact factor: 15.609
Authors: Kanika Bajaj Pahuja; Thong T Nguyen; Bijay S Jaiswal; Kumar Prabhash; Tarjani M Thaker; Kate Senger; Subhra Chaudhuri; Noelyn M Kljavin; Aju Antony; Sameer Phalke; Prasanna Kumar; Marco Mravic; Eric W Stawiski; Derek Vargas; Steffen Durinck; Ravi Gupta; Arati Khanna-Gupta; Sally E Trabucco; Ethan S Sokol; Ryan J Hartmaier; Ashish Singh; Anuradha Chougule; Vaishakhi Trivedi; Amit Dutt; Vijay Patil; Amit Joshi; Vanita Noronha; James Ziai; Sripad D Banavali; Vedam Ramprasad; William F DeGrado; Raphael Bueno; Natalia Jura; Somasekar Seshagiri Journal: Cancer Cell Date: 2018-10-25 Impact factor: 31.743
Authors: Yanyan Lou; Chad V Pecot; Hai T Tran; Vikki J DeVito; Xi Ming Tang; John V Heymach; Raja Luthra; Ignacio I Wistuba; Zhuang Zuo; Anne S Tsao Journal: Clin Lung Cancer Date: 2015-11-17 Impact factor: 4.785